A Phase 1 interventional study of Tadalafil in Benign Prostatic Hyperplasia, sponsored by Eli Lilly and Company. Completed at 1 site in Germany. Open to male participants aged 45 Years and older. Per ClinicalTrials.gov, last updated 2012-05-16.
Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 26 studies testing tadalafil in Prostatic Hyperplasia — 2 open to participants now, 2 under way, none of them phase 3. Tadalafil · Prostatic Hyperplasia.
Among the 26 studies testing tadalafil in Prostatic Hyperplasia, this one is the 26th largest by enrollment, is one of 3 that started in 2010, is one of 5 in phase 1, and was the 13th registered.
828 studies on the registry are indexed under Prostatic Hyperplasia; 179 are open to participants now.
Browse Prostatic Hyperplasia studies →2 of the 26 studies testing tadalafil in Prostatic Hyperplasia are open now, in 1 country. Recruiting first, the newest first:
Beni-Suef University · Sites in Egypt
Ages 50+ · Men only
Assiut University
Men only
By country, each count listing its studies:
Tadalafil: first FDA approval 2003 (CIALIS), first EMA approval 2002. What it is approved for, and how studies give it, is on its page →
Of the 102 Prostatic Hyperplasia studies recruiting now, 70 (69%) set no upper age limit and 4 (4%) stop at 75 or younger; 7 take children under 18; 7 take healthy volunteers.
This study: 45 Years and older · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
26 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 5 · Phase 3 11 · Phase 4 6
First in 2004; this study’s year is marked. 3 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 24 is below the median of 92 across 627 interventional studies indexed under Prostatic Hyperplasia.
Median enrollment 258 across the 26 interventional studies. Of the 23 that completed or were terminated, 15 (65%) have results posted.
This tab as a report to print or save as PDF → With an account.
20 of 26 have an industry lead sponsor. The 10 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
17 studies in Prostatic Hyperplasia by Eli Lilly and Company: none open now, none under way, none of them phase 3. Of 17 finished, 16 (94%) have results posted.
Among the 17 studies in Prostatic Hyperplasia by Eli Lilly and Company, this one is the 17th largest by enrollment, is one of 4 that started in 2010, is the only one in phase 1, and was the 14th registered.
Eli Lilly and Company’s Prostatic Hyperplasia studies by the year they started, since 2004.
1 of the studies testing tadalafil in Prostatic Hyperplasia that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07654413Beni-Suef UniversityTamsulosin With or Without Tadalafil for Trial Without Catheter After Acute Urinary Retention Due to Benign Prostatic Hyperplasia | 2027-11 |
Add it to your calendar (.ics) → With an account.
Among the 26 studies testing tadalafil in Prostatic Hyperplasia, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Eli Lilly and Company’s 17 in Prostatic Hyperplasia:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to investigate the pharmacokinetics of tadalafil in Japanese and non-Japanese men with Benign Prostatic Hyperplasia (BPH).
The safety of tadalafil will also be studied.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
5 mg, administered orally, daily for 10 days
Drug: Tadalafil
5 mg, administered orally, daily for 10 days
Also known as: LY450190, Cialis, Adcirca
Pharmacokinetics: Area Under the Concentration Curve (AUC) for Tadalafil and Metabolite IC710
AUC for Day 1 is reported as AUC(tau \[t\], day 1), which is AUC from time zero to 24 hours (t) postdose on Day 1. AUC for Day 10 is reported as AUC(t,steady state \[ss\]), which is AUC during one 24-hour dosing interval at steady-state.
Time frame: 1 day and 10 days
Pharmacokinetics: Concentration Maximum (Cmax) of Tadalafil and Metabolite IC710
Time frame: 1 day and 10 days
Pharmacokinetics: Time to Concentration Maximum (Tmax) of Tadalafil and Metabolite IC710
Time frame: 1 day and 10 days
| Milestone | Japanese Participants | Caucasian Participants |
|---|---|---|
| Started | 12 | 12 |
| Completed | 12 | 12 |
| Not completed | 0 | 0 |
AUC for Day 1 is reported as AUC(tau \[t\], day 1), which is AUC from time zero to 24 hours (t) postdose on Day 1. AUC for Day 10 is reported as AUC(t,steady state \[ss\]), which is AUC during one 24-hour dosing interval at steady-state.
| nanograms*hour/milliliter (ng*hr/mL) | Japanese Participants | Caucasian Participants |
|---|---|---|
| Day 1 Tadalafil | 1410 ± 31 | 1340 ± 17 |
| Day 10 Tadalafil | 2710 ± 27 | 3410 ± 51 |
| Day 1 Metabolite IC710 | 525 ± 27 | 399 ± 23 |
| Day 10 Metabolite IC710 | 2270 ± 30 | 2290 ± 48 |
| nanograms per milliliter (ng/mL) | Japanese Participants | Caucasian Participants |
|---|---|---|
| Day 1 Tadalafil | 102 ± 27 | 104 ± 19 |
| Day 10 Tadalafil | 173 ± 24 | 215 ± 36 |
| Day 1 Metabolite IC710 | 32.1 ± 25 | 24.0 ± 26 |
| Day 10 Metabolite IC710 | 105 ± 31 | 102 ± 47 |
| hours | Japanese Participants | Caucasian Participants |
|---|---|---|
| Day 1 Tadalafil | 4.00 (1.00 to 4.00) | 2.00 (1.00 to 4.00) |
| Day 10 Tadalafil | 3.00 (2.00 to 4.00) | 2.53 (1.00 to 4.00) |
| Day 1 Metabolite IC710 | 23.83 (23.83 to 23.83) | 24.00 (16.02 to 24.03) |
| Day 10 Metabolite IC710 | 4.00 (0.00 to 24.00) | 8.00 (0.00 to 24.00) |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Japanese Participants | — | 0/12 (0%) | 0/12 (0%) |
| Caucasian Participants | — | 0/12 (0%) | 12/12 (100%) |
| Event | Japanese Participants | Caucasian Participants |
|---|---|---|
| HeadacheNervous system disorders | 0/12 | 4/12 |
| MyalgiaMusculoskeletal and connective tissue disorders | 0/12 | 3/12 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 0/12 | 3/12 |
| DyspepsiaGastrointestinal disorders | 0/12 | 2/12 |
| FlatulenceGastrointestinal disorders | 0/12 | 2/12 |
| DizzinessNervous system disorders | 0/12 | 2/12 |
| Abdominal painGastrointestinal disorders | 0/12 | 1/12 |
| Bowel movement irregularityGastrointestinal disorders | 0/12 | 1/12 |
| DiarrhoeaGastrointestinal disorders | 0/12 | 1/12 |
| Dry mouthGastrointestinal disorders | 0/12 | 1/12 |
| Age Continuous(years) | Japanese Participants | Caucasian Participants | Total |
|---|---|---|---|
| Mean | 57.0 ± 9.9 | 60.6 ± 7.2 | 58.8 ± 8.7 |
| Sex: Female, Male(Participants) | Japanese Participants | Caucasian Participants | Total |
|---|---|---|---|
| Female | 0 | 0 | 0 |
| Male | 12 | 12 | 24 |
| Ethnicity (NIH/OMB)(Participants) | Japanese Participants | Caucasian Participants | Total |
|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 |
| Not Hispanic or Latino | 12 | 12 | 24 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Japanese Participants | Caucasian Participants | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 12 | 0 | 12 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 0 | 12 | 12 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(participants) | Japanese Participants | Caucasian Participants | Total |
|---|---|---|---|
| Germany | 0 | 12 | 12 |
| Japan | 12 | 0 | 12 |
The record gives a start of Jul 2010, a primary completion of Apr 2011 and a completion of Apr 2011. It does not say whether these dates are actual or estimated.
Results were first posted in May 2012, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tadalafil